Mylan enters MPP agreement over affordable hepatitis C generics
Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool (MPP), a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
9 October 2017 Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.
9 October 2017 Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.
9 October 2017 Gilead Sciences has signed licensing agreements with the Medicines Patent Pool (MPP) and generic companies to provide greater access to HIV treatment bictegravir.